Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study
Pierre Mordant MD, PhD, Solenn Brosseau, Bernard Milleron, Nicola Santelmo, Séverine Fraboulet-Moreau, Benjamin Besse, Alexandra Langlais, Dominique Gossot, Pascal-Alexandre Thomas, Jean-Louis Pujol, Charles Ricordel, Jeannick Madelaine, Régine Lamy, Clarisse Audigier-Valette, Pascale Missy, Hélène Blons, Fabrice Barlesi, Virginie Westeel, French Cooperative Thoracic Intergroup (IFCT), Pierre Mordant MD, PhD, Solenn Brosseau, Bernard Milleron, Nicola Santelmo, Séverine Fraboulet-Moreau, Benjamin Besse, Alexandra Langlais, Dominique Gossot, Pascal-Alexandre Thomas, Jean-Louis Pujol, Charles Ricordel, Jeannick Madelaine, Régine Lamy, Clarisse Audigier-Valette, Pascale Missy, Hélène Blons, Fabrice Barlesi, Virginie Westeel, French Cooperative Thoracic Intergroup (IFCT)
Abstract
Introduction: Molecular profile of resected stage I-II non-small cell lung cancer (NSCLC) would help refine prognosis and personalize induction or adjuvant strategies. We sought to report the molecular profile of resected stage I-II NSCLC and analyzed the impact of epidermal growth factor receptor (EGFR) mutations on outcomes in a Western population.
Patients and methods: Surgical cases were identified from Biomarkers France study, a nationwide prospective study including NSCLC patients screened for EGFR, HER2, KRAS, BRAF, PIK3CA, ALK alterations from 2012 to 2013. Among surgical patients, clinical charts of the largest centers were reviewed in order to analyze the prognostic impact of EGFR mutations.
Results: In the BMF database (n = 17.636), surgical patients (n = 854) were characterized by a higher proportion of EGFR mutations than nonsurgical patients (12.9% vs. 10.2%, P = .025), while the other molecular alterations did not differ. The proportion of EGFR mutations was 27% in women undergoing surgery. In the study group (n = 293; EGFR wild type, n = 235; usual mutation, n = 50; rare mutation, n = 8), after a median follow-up of 67 months, 215 patients (74.4%) had not relapsed. No difference was found between EGFR-mutant and EGFR-wt tumors regarding recurrence site, disease-free survival, and overall survival. The 5-year disease-free survival and overall survival after surgical resection of stage I-II EGFR-mutated tumors were 65% and 75%, respectively.
Conclusion: In resected stage I to II NSCLC, EGFR mutations were found in 12.9% of cases, associated with a 5-year overall survival of 75%, with no impact on recurrence site, disease-free survival, and overall survival.
Keywords: NSCLC; Stage I-II disease; Surgery, Molecular profile, Prognosis.
Conflict of interest statement
Disclosure Dr Mordant, Dr Brosseau, Dr Milleron, Dr Santelmo, Dr Fraboulet, Mrs Langlais, Dr Gossot, Dr Thomas, Dr Pujol, Dr Madelaine, Dr Lamy, Dr Missy, Dr Blons report no conflict of interest. Dr Besse reports grants from Abbvie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE Immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, Tolero Pharmaceuticals, during the conduct of the study. Dr Ricordel reports grants from Novartis, outside the submitted work. Dr Audigier-Valette reports personal fees and non-financial support from Roche, BMS, MSD, AstraZeneca, Abbvie, Pfizer, Takeda outside the submitted work. Dr Barlesi reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda, outside the submitted work. Dr Westeel reports honoraria from Roche, AstraZeneca, BMS and MSD and non-financial support from Roche and Pfizer.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed